Research Article Details
| Article ID: | A35573 |
| PMID: | 20336392 |
| Source: | Obes Surg |
| Title: | A noninvasive clinical scoring model predicts risk of nonalcoholic steatohepatitis in morbidly obese patients. |
| Abstract: | BACKGROUND: A simple model to predict nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease is desirable to optimize the selection of patients for liver biopsy. We investigated a large group of morbidly obese patients to derive a scoring system based on simple clinical and laboratory variables. METHODS: Consecutive subjects undergoing bariatric surgery and without evidence of other liver disease or significant alcohol use underwent intraoperative liver biopsy. Demographic, clinical, and biochemical variables were collected. A scoring model was derived using variables found to be independent predictors of NASH. The scores were divided into four risk categories (low, intermediate, high, and very high). Positive and negative predictive values (PPV/NPV) were derived for each category and the area under the receiver operator curve (AUROC) was calculated. RESULTS: A total of 253 subjects were included: 52 (20.6%) had NASH, 116 (45.8%) had simple steatosis, and 85 (33.6%) had normal liver histology. Only ten subjects (19% of NASH group) had significant (>or= stage 2) fibrosis. Multivariate analysis identified diabetes, abnormal ALT, and hypertriglyceridemia as independent predictors of NASH. Sleep apnea showed a strong trend toward significance and was also included in the model. This model showed a NPV of 89.7% in the low risk category and a PPV of 75% in the very high risk category, with AUROC of 0.76. CONCLUSIONS: A simple scoring system performs well in predicting NASH and can be used in the clinic to optimize the selection of morbidly obese patients for liver biopsy. |
| DOI: | 10.1007/s11695-010-0118-y |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S09 | Bariatric surgery | Metabolic surgery | -- | -- | Details |
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I13 | 3146 | Lipid metabolism disorder | An inherited metabolic disorder that involves the creation and degradation of lipids. http://en.wikipedia.org/wiki/Lipid_metabolism | disease of metabolism/ inherited metabolic disorder | Details |
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|